Glaucoma News and Research

Latest Glaucoma News and Research

Obesity associated with decreased risk of open-angle glaucoma in women, not men

Obesity may be associated with higher eye pressure and a decreased risk of open-angle glaucoma in women but not men, according to a report posted online today that will appear in the May issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

14 Feb 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

11 Feb 2011

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

QLT Inc. today announced results from a Phase II proof-of-concept clinical trial for the olopatadine punctal plug delivery system (O‑PPDS).

9 Feb 2011

Two new studies report GOT may improve health outcomes of stroke patients

Much of the devastation of stroke and head trauma is due to damage caused the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don't cross the so-called blood-brain barrier, and those that do often don't work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.

9 Feb 2011

Vascular birthmarks can cause concern for parents: Dermatologists

Vascular birthmarks, which occur in nearly 10 percent of all infants at birth or within the first few weeks of life, can cause concern for parents particularly if they are large or in a cosmetically important area. The decision to treat a birthmark is one that parents should make with a dermatologist, who can determine the type of birthmark and whether or not it poses any potential risks in the future.

5 Feb 2011

Ocular Therapeutix closes $14 million Series D financing round

Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.

3 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Alcon fourth quarter sales raise 5.7% to $1.81 billion in 2010

Alcon, Inc. reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales growth in the quarter, while foreign currency fluctuations reduced reported sales growth by 20 basis points.

27 Jan 2011

Surge in cataract surgeries fuels intraocular lens market to almost $1.4 billion

According to two new reports by iData Research, the leading global authority in medical device and pharmaceutical market research, growth in the use of optical coherence tomography (OCT) for the detection of ocular conditions will drive the U.S. diagnostic ophthalmic market to over $650 million by 2017.

12 Jan 2011

ACADIA raises $15 million through private placement

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterprise Associates and Venrock.

10 Jan 2011

CeNeRx commences TriRima Phase II trial for treatment resistant depression

CeNeRx BioPharma, today reported that it has initiated a Phase II trial of its new formulation of TriRima, the company's novel antidepressant in development as monotherapy for treatment resistant depression.

7 Jan 2011

Regular eye exams are critical to prevent glaucoma

Glaucoma is the second leading cause of blindness, may strike without symptoms, is not preventable, but it is treatable. During National Glaucoma Awareness Month, The Minnesota Optometric Association (MOA) urges regular eye exams because early detection and treatment is critical to maintain healthy vision and protect the eyes from the effects of glaucoma and other potentially blinding diseases.

6 Jan 2011

Researchers develop new hand-held instrument for glaucoma screening

A new hand-held instrument involving a system of micro-force sensors, specially designed microchips, and math-based programmed procedures has been designed by researchers at the UA College of Engineering. The easy-to-use probe gently rubs the eyelid and can be used at home, threatening to replace painful eye drops and the need for a sterilized sensor.

5 Jan 2011

Get examined during Glaucoma Awareness Month

It happens slowly. Over time, a person's vision will get worse. Until one day, that person can no longer see. Glaucoma is the second leading cause of blindness in the United States and worldwide. Unfortunately, there is no cure. Once a person's vision is lost, it cannot be regained. That is why Dr. Bizer's VisionWorld is encouraging people to get an examination during Glaucoma Awareness Month.

5 Jan 2011

PanOptica completes $30 million Series A financing

PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock Ventures.

4 Jan 2011

Researchers identify new biological pathway that contribute to glaucoma

In a study published today in the Proceedings of the National Academy of Sciences, a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss.

4 Jan 2011

Glaucoma News and Research

Latest Glaucoma News and Research

Obesity associated with decreased risk of open-angle glaucoma in women, not men

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Clinical Data reports $2.0 million revenue for third quarter 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

Two new studies report GOT may improve health outcomes of stroke patients

Vascular birthmarks can cause concern for parents: Dermatologists

Ocular Therapeutix closes $14 million Series D financing round

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Alcon fourth quarter sales raise 5.7% to $1.81 billion in 2010

Surge in cataract surgeries fuels intraocular lens market to almost $1.4 billion

ACADIA raises $15 million through private placement

CeNeRx commences TriRima Phase II trial for treatment resistant depression

Regular eye exams are critical to prevent glaucoma

Researchers develop new hand-held instrument for glaucoma screening

Get examined during Glaucoma Awareness Month

PanOptica completes $30 million Series A financing

Researchers identify new biological pathway that contribute to glaucoma

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in